🚀 VC round data is live in beta, check it out!
Samchundang Pharm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Samchundang Pharm and similar public comparables like 3SBio, PharmaEssentia, Gedeon Richter, ALK and more.
Samchundang Pharm Overview
About Samchundang Pharm
Samchundang Pharm Co Ltd is engaged in manufacturing, distributing, importing, and exporting pharmaceuticals in South Korea. The company offers ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as gastro intestines and vitamins.
Founded
1943
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$8B
Samchundang Pharm Financials
Samchundang Pharm reported last fiscal year revenue of $157M and EBITDA of $17M.
In the same fiscal year, Samchundang Pharm generated $74M in gross profit, $17M in EBITDA, and $4M in net income.
Samchundang Pharm P&L
In the most recent fiscal year, Samchundang Pharm reported revenue of $157M and EBITDA of $17M.
Samchundang Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $157M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $74M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 47% | XXX | XXX | XXX |
| EBITDA | — | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 4% | XXX | XXX | XXX |
| Net Profit | — | XXX | $4M | XXX | XXX | XXX |
| Net Margin | — | XXX | 2% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Samchundang Pharm Stock Performance
Samchundang Pharm has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Samchundang Pharm's stock price is $328.50.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | -4.1% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSamchundang Pharm Valuation Multiples
Samchundang Pharm trades at 48.5x EV/Revenue multiple, and 458.6x EV/EBITDA.
Samchundang Pharm Financial Valuation Multiples
As of April 18, 2026, Samchundang Pharm has market cap of $8B and EV of $8B.
Equity research analysts estimate Samchundang Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Samchundang Pharm has a P/E ratio of 2146.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 48.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 458.6x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 1326.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 102.7x | XXX | XXX | XXX |
| P/E | — | XXX | 2146.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (225.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Samchundang Pharm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Samchundang Pharm Margins & Growth Rates
Samchundang Pharm's revenue in the last fiscal year grew by 10%.
Samchundang Pharm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 20% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 44% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Samchundang Pharm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Samchundang Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| 3SBio | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaEssentia | XXX | XXX | XXX | XXX | XXX | XXX |
| Gedeon Richter | XXX | XXX | XXX | XXX | XXX | XXX |
| ALK | XXX | XXX | XXX | XXX | XXX | XXX |
| Wantai BioPharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Samchundang Pharm M&A Activity
Samchundang Pharm acquired XXX companies to date.
Last acquisition by Samchundang Pharm was on XXXXXXXX, XXXXX. Samchundang Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Samchundang Pharm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSamchundang Pharm Investment Activity
Samchundang Pharm invested in XXX companies to date.
Samchundang Pharm made its latest investment on XXXXXXXX, XXXXX. Samchundang Pharm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Samchundang Pharm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Samchundang Pharm
| When was Samchundang Pharm founded? | Samchundang Pharm was founded in 1943. |
| Where is Samchundang Pharm headquartered? | Samchundang Pharm is headquartered in South Korea. |
| Who is the CEO of Samchundang Pharm? | Samchundang Pharm's CEO is In-seok Jeon. |
| Is Samchundang Pharm publicly listed? | Yes, Samchundang Pharm is a public company listed on Korea Exchange. |
| What is the stock symbol of Samchundang Pharm? | Samchundang Pharm trades under 000250 ticker. |
| When did Samchundang Pharm go public? | Samchundang Pharm went public in 2000. |
| Who are competitors of Samchundang Pharm? | Samchundang Pharm main competitors are 3SBio, PharmaEssentia, Gedeon Richter, ALK. |
| What is the current market cap of Samchundang Pharm? | Samchundang Pharm's current market cap is $8B. |
| What is the current revenue of Samchundang Pharm? | Samchundang Pharm's last fiscal year revenue is $157M. |
| What is the current EV/Revenue multiple of Samchundang Pharm? | Current revenue multiple of Samchundang Pharm is 48.5x. |
| Is Samchundang Pharm profitable? | No, Samchundang Pharm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.